Immune checkpoint inhibitors (ICIs), PARP inhibitors, VEGF inhibitors, kinase inhibitors, and chemotherapy are all being used in various combinations for the treatment of endometrial and ovarian cancers. As these new combinations seek to further improve and enhance the efficacy of treatment, the risk of AEs increases. During this informational podcast, Dr. Richard Penson and Ms. Jennifer Filipi will educate clinicians on the prevention, mitigation, and management of AEs that arise from these new combination regimens.
- Provider:CME Outfitters, LLC
- Activity Link: https://www.cmeoutfitters.com/activity/adverse-events-in-the-new-age-of-front-line-combination-approaches-in-advanced-gynecologic-cancers/
- Start Date: 2024-04-29 05:00:00
- End Date: 2024-04-29 05:00:00
- Credit Details: IPCE Credits: 0.5 hours
AAPA Category 1 Credit™️: 0.5 hours
AMA PRA Category 1 Credit™️: 0.5 hours
Nursing: 0.5 hours
Pharmacy: 0.5 hours - MOC Credit Details: ABIM - 0.5 Point; Credit Type(s): Medical Knowledge (ABIM)
- Commercial Support: Source: AstraZeneca (Any division) - Amount: 0 - Is Kind Support: False Source: Merck (Any division) - Amount: 0 - Is Kind Support: False
- Activity Type: Enduring Material
- CME Finder Type: Online Learning
- Fee to Participate: No, it's free
- Measured Outcome: Learner/Team Competence
- Provider Ship: Directly Provided
- Registration: Open to all
- Specialty: Internal Medicine
Subscribe
Login
0 Comments
Oldest